



To:

THE DIRECTOR GENERAL OF HEALTH SERVICES IN ALL GOVERNORATES

Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)

Director General of Engineering Affairs, MOH

Director General of Royal Hospital

Director General of Khoula Hospital

Director General of Medical Supplies (MOH)

Director General of Pvt. Health Est. Affairs (to kindly arrange distribution to all Pvt. Hospitals)

Hospital Director (Al Nahda Hospital)

Hospital Director (Al Massara Hospital)

The Head of Medical Services in SQU Hospital

The Head of Medical Services in Royal Oman Police

The Head of Medical Services in Ministry of Defence

The Head of Medical Services in The Diwan

The Head of Medical Services in The Sultan's Special Force

The Head of Medical Services in Internal Security Services

The Head of Medical Services in Petroleum Development of Oman

The Head of Medical Services in LNG Oman

ALL PRIVATE PHARMACIES & DRUG STORES

After Compliments,

Please find attached our Circular No 90 dated 30/4/2023 Regarding NCMDR FSN of BD Kiestra Inoqula+ from (mfr: BD Switzerland Sarl).

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Medical Device Control, DGPA&DC
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Supdt. of Central Drug Information





Circular No.

901/2023

نتقدم بيقين
Moving Forward
with Confidence



09 -10-1444 H

30 -04-2023

Field Safety Notice of BD Kiestra InoqlA+ from BD Switzerland Sarl.

Source	NCMDR-National Center for Medical Device Reporting https://ncmdr.sfda.gov.sa/Secure/CA/CAViewRecall.aspx?caid=4&rid=19491
Product	BD Kiestra InoqlA+.
Description	Sample processing system.
Manufacturer	BD Switzerland Sarl.
The affected products	Product Code (REF): 447213, UDI: 038290LSUVLPKFPV, Manufacturer's SRN: NL-MF-000018863, Serial Numbers: 20130276, 19033ST002.
Reason	Upon installation of BD Kiestra InoqlA+ and BeA version 5.1 and 5.1.1 as part of the Icefall A platform that plat information was not visible in Synapsys after processing has occurred.
Action	<ol style="list-style-type: none">1. Customers should utilize the module of the Icefall platform identified by their regional BD service team that does not exhibit this issue to avoid possible unavailability of results.2. BD has developed and remotely implemented an interim solution to immediately address the software issue and prevent disruption of testing for the patients.3. Contact the local agent for remedial action.
Product Image	
comments	Healthcare professionals are encouraged to report any adverse events Suspected to be associated with the above device or any other medical device to Department of Medical Device Control through the E-mail: Med-device@moh.gov.om

AS
/ Dr. Mohammed Hamdan Al Rubaie

Director General

